News

Cidara Therapeutics Announces Inducement Grant Under Nasdaq Rule

Cidara Therapeutics Announces Inducement Grant Under Nasdaq Rule

Cidara Therapeutics Reveals New Employee Incentive

Cidara Therapeutics, Inc. (NASDAQ: CDTX), a notable biotechnology company dedicated to advancing healthcare through innovative drug-Fc conjugate (DFC) immunotherapies, has taken significant steps to enhance its team. This move is critical in their ongoing mission to improve the quality of care for patients facing serious diseases. Recently, the Compensation Committee of the Board of Directors granted an inducement stock option and restricted stock units (RSUs) totaling 1,110 shares of common stock to a new employee, Dipesh Bhatt.

Details of the Stock Option Award

The stock option award comes under the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, which is pivotal for attracting fresh talent. The grant date for this award was set for September 30, 2024, and the exercise price is established at $10.75 per share—matching the closing price on that same day. The option shares will become vested over a four-year period. This vesting schedule means that after one year, 25% of the stock options will be available to Bhatt, with the remaining shares vesting in equal monthly installments.

Vesting and Conditions

It's important to note that all restricted stock units will vest in four equal annual installments. This structured approach to vesting is not only a standard practice but also a smart way to encourage long-term commitment from employees, ensuring they align their career growth with the success of Cidara Therapeutics.

About the Inducement Plan

The inducement equity grant is designed as a recruitment mechanism for promising individuals who have not been previous employees of the company or those returning after a significant hiatus. This strategy is in accordance with Nasdaq Listing Rule 5635(c)(4) and represents a vital part of Cidara’s approach to building a robust workforce prepared to tackle the complexities of drug development.

Correction of an Earlier Announcement

It is worth noting that there was a correction made regarding a previous press release dated August 19, 2024. An administrative error had reported Jim Beitel receiving a total of 71,000 shares; however, the correct figure is 81,000 shares of its common stock awarded under the same Inducement Plan. Such corrections are crucial for maintaining transparency and trust in corporate communications.

Exploring Cidara's Innovations

Cidara Therapeutics is utilizing its proprietary Cloudbreak platform to pioneer drug-Fc conjugates, which blend targeted small molecules and engineered antibody fragments. Among its innovative drug candidates, CD388 stands out as a long-acting antiviral developed to enhance preventive measures against influenza. This candidate has successfully achieved Fast Track Designation from the U.S. Food and Drug Administration (FDA). In ongoing efforts, the company is also set to launch a Phase 2b clinical trial.

Focus on Oncology

Investment in oncology therapy is also a key aspect of the company’s strategic direction. In July 2024, Cidara received Investigational New Drug (IND) clearance for CBO421, aiming to target CD73 in solid tumors. These developments underscore the company’s commitment to addressing a wide range of serious health conditions through innovative solutions.

Contact Information

For further inquiries, Cidara encourages reaching out via their investor relations representative, Brian Ritchie at LifeSci Advisors, available at (212) 915-2578. Additionally, the media contact, Michael Fitzhugh of LifeSci Communications, can be reached via email.

Frequently Asked Questions

1. What is the significance of the inducement grant?

The inducement grant serves to attract new talent to Cidara Therapeutics, incentivizing long-term commitment and aligning employee success with company goals.

2. Who received the stock option award?

The stock option award was granted to Dipesh Bhatt, a new employee of Cidara Therapeutics.

3. What is Cidara’s main product?

Cidara's primary product candidate is CD388, an antiviral designed for influenza prevention.

4. How does the vesting schedule work?

The vesting schedule allows 25% of the awarded shares to vest after one year, with the remaining shares vesting in equal monthly installments thereafter.

5. How does Cidara contribute to oncology?

Cidara is developing oncology therapies, including CBO421, which targets CD73 in solid tumors.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 28

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 161

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 342

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 24

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Mercy Medical Center Nurses Mobilize for Patient Safety Picket

Updated Category News Views 35

Nurses Standing Together for Patient Safety Nurses at Mercy Medical Center are uniting for a cause that affects them profoundly: the safety of their patients and the workplace. With issues surrounding unsafe staffing and deteriorating care conditions, nurses represented by the Massachusetts Nurses Association plan to hold an informational picket. This demonstration is not...

Continue Reading
Massive Merger: Qorvo and Skyworks Unite for Future Innovations

Updated Category News Views 306

Overview of the Strategic Merger In an exciting development in the technology sector, shares of Qorvo, Inc. (NASDAQ: QRVO) and Skyworks Solutions, Inc. (NASDAQ: SWKS) are experiencing a notable surge after announcing their intent to merge. This deal, which values the combined entity at approximately $22 billion, marks a significant step forward in the realm of...

Continue Reading
Oryzon Genomics Announces Corporate Updates for September

Updated Category News Views 178

Oryzon Genomics to Share Updates on Corporate Progress Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a leading clinical-stage biopharmaceutical company dedicated to epigenetic therapies for critical medical needs, is set to present its latest corporate updates at several major international events. These important gatherings scheduled for September will showcase...

Continue Reading
Envision Energy Launches Innovative Energy Storage Solution

Updated Category News Views 363

Introducing the EN 8 Pro: A Revolution in Energy Storage Envision Energy, a leader in sustainable technology, has made a significant breakthrough in energy management with the launch of its EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System. This innovative setup is set to establish new industry standards in safety, efficiency, and environmental adaptability. Designed...

Continue Reading
Beard Papa's Teams Up for Exciting Zenless Zone Zero Launch

Updated Category News Views 528

Beard Papa's Exciting Flavor Collaboration Begins Beard Papa's, renowned for its delectable cream puffs and irresistible custard fillings, is thrilled to announce a nationwide collaboration with Zenless Zone Zero. This partnership will launch an exciting in-game event that will allow fans to experience the unique flavors inspired by the action-RPG sensation from...

Continue Reading